Turn Therapeutics Inc. — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Turn Therapeutics (biotech, $18.6M assets) shared a July 2026 investor presentation showing Phase 2 interim results for GX-03 in atopic dermatitis: in a representative subgroup (n=25, enriched for baseline pruritus ≥7), GX-03 met four prespecified endpoints versus vehicle with p-values ranging 0.0100–0.0914, including 61.5% vs 8.3% Week 4 vIGA-AD success (Δ 53.2%, p=0.0100). Full Stage 2 (~135 patients) enrollment ongoing; topline Q4 2026. Company reports $11.2M cash as of March 31, 2026, and runway into Q3 2027. GX-03 also in development for onychomycosis (Phase 3 planned Q1 2027) and hidradenitis suppurativa (Phase 2a planned Q2 2027).
Why this rating
Interim efficacy signals across all four AD endpoints with statistical significance on primary measure support Phase 3 likelihood. Company remains pre-commercial and cash-constrained (runway ~18 months relative to ~$250K/mo burn); near-term capital need is material. Pipeline in three indications is material for a $18.6M-asset company. Event is significant for trajectory but not yet transformational—approval years away, funding risk present.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.